Carcinoma in situ of right bronchus and lung
ICD-10 D02.21 is a billable code used to indicate a diagnosis of carcinoma in situ of right bronchus and lung.
Carcinoma in situ (CIS) of the right bronchus and lung refers to a localized form of lung cancer where abnormal cells are present in the lining of the bronchus and lung but have not invaded deeper tissues or spread to other parts of the body. This condition is characterized by the presence of atypical cells that have the potential to develop into invasive cancer if left untreated. The diagnosis is typically made through imaging studies such as CT scans and confirmed via bronchoscopy and biopsy. Patients with CIS may be asymptomatic or present with respiratory symptoms, including cough or hemoptysis. Surveillance protocols often involve regular imaging and pulmonary function tests to monitor for progression to invasive disease. The risk of progression to invasive carcinoma varies based on factors such as the size and histological characteristics of the lesion, as well as patient-specific factors like smoking history and overall health. Early detection and intervention are crucial in managing this condition effectively.
Detailed imaging reports, biopsy results, and treatment plans.
Diagnosis of CIS during routine screenings or evaluation of respiratory symptoms.
Ensure clear documentation of the site and characteristics of the carcinoma.
Comprehensive treatment plans, follow-up notes, and pathology reports.
Management of patients with CIS and planning for potential interventions.
Documenting the rationale for surveillance and treatment decisions.
Used for diagnosis and evaluation of CIS.
Document indication for bronchoscopy and findings.
Pulmonologists must ensure accurate reporting of findings.
Accurate coding of D02.21 is crucial for proper treatment planning, reimbursement, and ensuring that patients receive appropriate surveillance for potential progression to invasive cancer.
